Kuon Ruben-J, Voß Pauline, Rath Werner
Universitätsklinikum Heidelberg, Abteilung für Gynäkologische Endokrinologie und Fertilitätsstörungen, Frauenklinik, Heidelberg, Germany.
Medizinische Fakultät Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Geburtshilfe Frauenheilkd. 2019 Aug;79(8):844-853. doi: 10.1055/a-0854-6472. Epub 2019 Aug 12.
The prevention and treatment of preterm birth remains one of the biggest challenges in obstetrics. Worldwide, 11% of all children are born prematurely with far-reaching consequences for the children concerned, their families and the health system. Experimental studies suggest that progesterone inhibits uterine contractions, stabilises the cervix and has immunomodulatory effects. Recent years have seen the publication of numerous clinical trials using progestogens for the prevention of preterm birth. As a result of different inclusion criteria and the use of different progestogens and their methods of administration, it is difficult to draw comparisons between these studies. A critical evaluation of the available studies was therefore carried out on the basis of a search of the literature (1956 to 09/2018). Taking into account the most recent randomised, controlled studies, the following evidence-based recommendations emerge: In asymptomatic women with singleton pregnancies and a short cervical length on ultrasound of ≤ 25 mm before 24 weeks of gestation (WG), daily administration of vaginal progesterone (200 mg capsule or 90 mg gel) up until 36 + 6 WG leads to a significant reduction in the preterm birth rate and an improvement in neonatal outcome. The latest data also suggest positive effects of treatment with progesterone in cases of twin pregnancies with a short cervical length on ultrasound of ≤ 25 mm before 24 WG. The study data for the administration of progesterone in women with singleton pregnancies with a previous preterm birth have become much more heterogeneous, however. It is not possible to make a general recommendation for this indication at present, and decisions must therefore be made on a case-by-case basis. Even if progesterone use is considered to be safe in terms of possible long-term consequences, exposure should be avoided where it is not indicated. Careful patient selection is crucial for the success of treatment.
早产的预防和治疗仍然是产科领域最大的挑战之一。在全球范围内,11%的儿童早产,这给相关儿童、其家庭和卫生系统带来了深远影响。实验研究表明,孕酮可抑制子宫收缩、稳定宫颈并具有免疫调节作用。近年来,发表了大量使用孕激素预防早产的临床试验。由于纳入标准不同、使用的孕激素及其给药方法各异,很难对这些研究进行比较。因此,基于文献检索(1956年至2018年9月)对现有研究进行了批判性评估。考虑到最新的随机对照研究,得出以下基于证据的建议:对于妊娠24周前(WG)超声检查宫颈长度≤25mm的单胎妊娠无症状女性,每天阴道给予孕酮(200mg胶囊或90mg凝胶)直至妊娠36+6周,可显著降低早产率并改善新生儿结局。最新数据还表明,对于妊娠24周前超声检查宫颈长度≤25mm的双胎妊娠,孕酮治疗也有积极效果。然而,对于有早产史的单胎妊娠女性使用孕酮的研究数据则更为多样。目前无法针对该适应症给出一般性建议,因此必须逐案做出决定。即使认为使用孕酮在可能的长期后果方面是安全的,但在无适应症时也应避免暴露。仔细选择患者对于治疗成功至关重要。